Self-Assembling Peptide Nanofiber Scaffolds, Platelet-Rich Plasma, and Mesenchymal Stem Cells for Injectable Bone Regeneration With Tissue Engineering
Self-Assembling Peptide Nanofiber Scaffolds, Platelet-Rich Plasma, and Mesenchymal Stem Cells for Injectable Bone Regeneration With Tissue Engineering
复制标题
DOI：
10.1097/scs.0b013e3181b09b7e
复制
发表时间：
2009-09-01
影响因子：
0.9
通讯作者：
Ueda, Minoru
中科院分区：
文献类型：
--
作者：
Yoshimi, Ryoko;Yamada, Yoichi;Ueda, Minoru
本研究的目的是研究 PuraMatrix (PM)（一种自组装肽纳米材料）与狗间充质干细胞 (dMSC) 和/或富血小板血浆 (PRP) 结合使用组织工程和再生技术作为骨再生支架的能力。最初，牙齿是从成年杂交狗的下颌区域拔除的。 4周后，用环锯棒在下颌骨两侧制备骨缺损。将以下移植材料植入这些缺损中：(1) 对照（仅缺损）、(2) PM、(3) PM/PRP、(4) PM/dMSCs 和 (5) PM/dMSCs/PRP。从扫描电镜图像来看，PM具有三维纳米结构，dMSCs附着在PM表面。植入后 2、4 和 8 周，用环钻棒从移植区域收集每个样本，并通过组织学和组织形态计量学分析进行评估。观察到PM/dMSCs/PRP再生的骨质量优良，且已形成成熟骨。组织测量上，第 8 周时，新形成的骨面积包括 12.39 +/- 1.29%（对照）、25.28 +/- 3.92%（PM）、27.72 +/- 3.15%（PM/PRP）、50.07 +/- 3.97%（PM/dMSC）和 58.43 +/- 5.06% （PM/dMSC/PRP）。与对照组、PM 或 PM/PRP 相比，PM/dMSCs 和 PM/dMSCs/PRP 组在所有周均表现出显着增加（P
The purpose of this study was to investigate a capability of PuraMatrix (PM), which is a self-assembling peptide nanomaterial, as a scaffold for bone regeneration in combination with dog mesenchymal stem cells (dMSCs) and/or platelet-rich plasma (PRP) using tissue engineering and regenerative technology. Initially, teeth were extracted from an adult hybrid dog's mandible region. After 4 weeks, bone defects were prepared on both sides of the mandible with a trephine bar. The following graft materials were implanted into these defects: (1) control (defect only), (2) PM, (3) PM/PRP, (4) PM/dMSCs, and (5) PM/dMSCs/PRP. From scanning electron microscope images, PM had a three-dimensional nanostructure, and dMSCs attached on the surface of PM. At 2, 4, and 8 weeks after implantation, each sample was collected from the graft area with a trephine bar and assessed by histologic and histomorphometric analyses. It was observed that the bone regenerated by PM/dMSCs/PRP was of excellent quality, and mature bone had been formed. Histometrically, at 8 weeks, newly formed bone areas comprised 12.39 +/- 1.29% (control), 25.28 +/- 3.92% (PM), 27.72 +/- 3.15% (PM/PRP), 50.07 +/- 3.97% (PM/dMSCs), and 58.43 +/- 5.06% (PM/dMSCs/PRP). The PM/dMSCs and PM/dMSCs/PRP groups showed a significant increase at all weeks compared with the control, PM, or PM/PRP (P